
Strides Pharma to acquire arms of Endo in U.S for $24 mn
The Hindu
With this acquisition, Strides would have doubled its US portfolio with the potential to launch 5-6 new products each quarter going forward.
City-based Strides Pharma Science Limited (Strides) on Friday said its wholly-owned subsidiaries have entered into definitive agreements with subsidiaries of Endo International plc (Endo) to acquire its manufacturing facility at Chestnut Ridge, New York, for $ 24 million. The new portfolio has 20 commercial products and a basket of dormant ANDAs (abbreviated new drug applications) that are expected to fast track Strides’ new product launch strategy for US markets, as per the communique.More Related News

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












